Phase II Trials of Fosquidone in Cancer
Author Information
Author(s): S.B. Kaye, M. Brampton, P. Harper, J. Smyth, D.J. Kerr, M. Gore, J.A. Green, E. Gilby, S.M. Crawford, G.J. Rustin
Primary Institution: Beatson Oncology Centre, Western Infirmary, Glasgow
Hypothesis
Does fosquidone have antitumor activity in patients with metastatic colorectal, renal, and non-small cell lung cancer?
Conclusion
Fosquidone showed no significant antitumor activity in the studied patient group.
Supporting Evidence
- 61 patients with metastatic cancer were treated in the trials.
- None of the patients had received prior chemotherapy.
- Treatment was well tolerated with mild side effects.
- Nine patients demonstrated stable disease for a median duration of 11 weeks.
Takeaway
Doctors tested a new cancer drug called fosquidone on patients, but it didn't help them get better.
Methodology
Patients received fosquidone intravenously for five days every three weeks, and their responses were assessed after two cycles of therapy.
Limitations
The study had a small sample size and no patients achieved an objective partial response.
Participant Demographics
Patients included 26 with colon cancer, 18 with non-small cell lung cancer, and 26 with renal cancer, with a median age of 57.
Want to read the original?
Access the complete publication on the publisher's website